Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-07-01
|
| Series: | Blood and Lymphatic Cancer : Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/use-of-carfilzomib-in-second-line-therapy-and-beyond-for-relapsed-mult-peer-reviewed-article-BLCTT |